Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area andSeverity Index (PSI)

April W Armstrong, 1 Mark Lebwohl, 1 Jerry Bagel, 1 Todd Schlesinger, 2 Subhashis Banerjee, 1 Renata M Kisa, 1 Thomas Scharnitz, 1 Kim Hoyt, 1 Bruce Strober 1, 3

University of Southern California, Los Angeles, CA, USA; 1 Icahn School of Medicine at Mount Sinai, New York, NY, USA; 1 Praxis Treatment Center of New Jersey, East Windsor, NJ, USA; 1 Clinical Research Center of the Carolinas, Charlotte, NC, USA; 1 Bristol Myers Squibb, Princeton, NJ, USA; 1 Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, USA

Introduction

Deucravacitinib (BMS-986085, deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. The selectivity of deucravacitinib for TYK2 over JAK1-3 has been demonstrated in vitro and in vivo.

Methods

Adult patients with moderate to severe plaque psoriasis (PASI ≥12, sPGA ≥3, BSA involvement ≥10%) were randomized to deucravacitinib 6 mg daily or placebo for 16 weeks, followed by blinded treatment switches at Week 16 and Week 24. The primary endpoint was PASI 75 (≥50% reduction from baseline in PASI) response rate at Week 16 in the POETYK PSO-1 and -2 pooled population.

Results

Baseline demographics:

Table 1: Baseline demographics by baseline BSA involvement and PASI score in the pooled POETYK PSO-1 and -2 population

<table>
<thead>
<tr>
<th>Group</th>
<th>BSA 10%–&lt;15%</th>
<th>BSA 15%–&lt;20%</th>
<th>BSA 20%–&lt;30%</th>
<th>BSA ≥30%</th>
<th>PASI 0</th>
<th>PASI 12</th>
<th>PASI 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo bourgeoisie</td>
<td>27 (42.2%)</td>
<td>4 (4.3%)</td>
<td>72 (37.1%)</td>
<td>5 (6.0%)</td>
<td>88.5</td>
<td>9848</td>
<td>88.5</td>
</tr>
<tr>
<td>Deucravacitinib 6 mg QD</td>
<td>31 (86.1%)</td>
<td>8 (22.4%)</td>
<td>27 (77.4%)</td>
<td>30 (90.9%)</td>
<td>98.6</td>
<td>88.5</td>
<td>88.5</td>
</tr>
</tbody>
</table>

Weeks 0, 16, 24:

Figure 5: PASI 75 response rates at Weeks 16 and 24 by baseline BSA involvement in the pooled POETYK PSO-1 and -2 population

Conclusions

Deucravacitinib was superior to placebo across all baseline body surface areas and PASI scores.

References


Acknowledgments

This work was supported by Bristol Myers Squibb. The authors declare no conflicts of interest. This study was presented at the EADV 30th Congress; September 29-October 2, 2021.

Presented at the Winter Clinical Dermatology Conference - Reno, Nevada; January 31, 2023; and Winter Clinical - Miami, Florida; February 11, 2023; Miami, FL.